KCNT1-Targeting Oligonucleotides for Drug-Resistant Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatments for infantile encephalopathies and pharmaco-resistant epilepsies, particularly those caused by KCNT1 gain of function mutations, which result in increased potassium channel activity and severe symptoms such as seizures and cognitive impairments.
Innovation Solution
Development of compounds and methods to reduce KCNT1 RNA and protein levels using modified oligonucleotides that are complementary to KCNT1 nucleic acid sequences, including oligomeric compounds with modified sugar moieties and internucleoside linkages, administered to target neurological conditions like EIMFS and ADNFLE.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for KCNT1-related epilepsies, then treatment options are limited, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent changes the therapeutic parameter from conventional antiepileptic drugs to oligomeric compounds with modified sugar moieties and internucleoside linkages. These compounds specifically target and reduce KCNT1 protein expression at the molecular level, providing a novel mechanism of action that overcomes the limitations of conventional treatments for KCNT1-related epilepsies
2Quantity of substance
If KCNT1 channel activity is increased due to gain of function mutations, then potassium current increases, but seizure severity worsens
Solution Approach 1:
The patent converts the harmful effect of increased KCNT1 channel activity into a beneficial therapeutic outcome by using oligomeric compounds that specifically bind to and reduce KCNT1 protein expression. This approach targets the root cause of the harmful potassium current increase, thereby reducing seizure severity and other harmful symptoms associated with KCNT1 gain of function mutations
3Quantity of substance
If oligomeric compounds with modifications are used to reduce KCNT1 RNA, then KCNT1 protein levels decrease, but molecular complexity increases
Solution Approach 1:
The patent applies local quality modifications by introducing specific modified sugar moieties and internucleoside linkages at particular positions within the oligomeric compound structure. These localized modifications enhance the compound's ability to bind to KCNT1 RNA and reduce protein expression, while the modular nature of the modifications allows for optimized design that balances effectiveness with manageable molecular complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce KCNT1 activity, ameliorating symptoms like seizures and cognitive impairments, providing therapeutic benefits for patients with pharmaco-resistant epilepsies.
Implementation Method 1
a modified oligonucleotide that is complementary to a KCNT1 nucleic acid sequence
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of KCNT1 RNA in a cell or subject, and in certain instances reducing the amount of KCNT1 protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurological condition. Such symptoms and hallmarks include seizures, encephalopathy, and behavioral abnormalities. Non-limiting examples of neurological conditions that benefit from these compounds, methods, and pharmaceutical compositions are epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, and Ohtahara syndrome.